Atossa Therapeutics, Inc. (NASDAQ: ATOS) has announced its Board of Directors' approval of a share repurchase program
Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical stage biopharmaceutical company focused on developing innovative medicines to address unmet needs in oncology, particularly breast cancer, has announced its Board of Directors' approval of a share repurchase program. The program authorizes the repurchase of up to $10 million worth of the company's common stock, with the initiative set to continue until December 31, 2023.
Confidence in Long-Term Prospects:Dr. Steven Quay, President and CEO of Atossa Therapeutics, expressed the company's commitment to generating long-term value for its stockholders through strategic capital deployment. Recognizing the current macroeconomic environment and the bright future of Atossa, the share repurchase program is seen as a unique opportunity to drive stockholder value. Atossa focuses on breast cancer and ongoing Phase 2 studies for its (Z)-endoxifen development program.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better trader.